Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabeti...
August 02 2017 - 8:30AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that it has been awarded a Phase 2 Small Business
Innovation Research (SBIR) grant by the National Institutes of
Health (NIH) of up to $997,068 over two years to conduct
preclinical research to evaluate the potential of NSI-189, a novel
small molecule compound, for the prevention and treatment of
diabetic neuropathy.
The research funded by this award will build on a previous study
performed in collaboration with Drs. Corinne Jolivalt’s and Nigel
Calcutt’s groups at the University of California, San Diego (UCSD),
that demonstrated NSI-189 could prevent and/or reverse peripheral
neuropathy in mouse models for Type 1 and Type 2 diabetes. NSI-189
was shown to significantly protect motor and sensory nerve function
in mice with Type 1 diabetes when given from onset of disease, and
improve nerve function when given 2 months after disease onset.
Similarly, NSI-189 protected motor and sensory nerve function in a
genetic model of Type 2 diabetes (db/db mouse).
“We look forward to continuing these important studies with UCSD
to better understand the potential of NSI-189 in treating diabetic
neuropathy,” said Rich Daly, chairman and CEO, Neuralstem.
“Diabetic neuropathy is a chronic and debilitating disease that
remains an unmet medical need, and we appreciate the NIH’s
recognition of the importance of this research.”
“The initial data obtained from our preclinical study with
Neuralstem’s compound showed improvement in almost all indices of
peripheral neuropathy. This is rather unique, and we look
forward to testing NSI-189 in greater depth with this funding,”
said Dr. Corinne Jolivalt, the lead collaborator at UCSD where the
animal study will take place and with whom the grant money will be
shared.
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. NSI-189 is a
small molecule in clinical development for major depressive
disorder (MDD) and in preclinical development for Angelman’s
syndrome, irradiation-induced cognitive impairment, Type 1 and Type
2 diabetes and stroke.
NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three months
ended March 31, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Contact:
Danielle Spangler
Director of Investor Relations, Neuralstem
301-366-1481
dspangler@neuralstem.com
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
Lori Rosen
LDR Communications (Public Relations)
917-553-6808
lori@ldrcommunications.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2024 to Jun 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Jun 2023 to Jun 2024